Ignite Creation Date:
2024-05-05 @ 10:35 PM
Last Modification Date:
2024-10-26 @ 10:21 AM
Study NCT ID:
NCT01143753
Status:
COMPLETED
Last Update Posted:
2017-07-28
First Post:
2010-06-11
Brief Title:
A Study of RO5212054 PLX3603 in Participants With BRAF V600-Mutated Advanced Solid Tumors
Sponsor:
Hoffmann-La Roche
Organization:
Hoffmann-La Roche
Study Overview
Official Title:
An Open-Label Multiple Ascending Dose MAD Study of the Selective BRAF Inhibitor RO5212054 PLX3603 to Evaluate Safety Tolerability and Pharmacokinetics in Patients With BRAF V600-Mutated Advanced Solid Tumours
Status:
COMPLETED
Status Verified Date:
2017-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This open-label multi-center study will evaluate the safety tolerability and pharmacokinetics of RO5212054 PLX3603 in participants with BRAF V600-mutated advanced solid tumors Cohorts of participants will receive escalating oral doses of RO5212054 Anticipated time on study treatment is until disease progression or unacceptable toxicity occurs
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2010-018330-42 | EUDRACT_NUMBER | None | None |